{"id":2199,"date":"2026-05-29T04:00:37","date_gmt":"2026-05-29T04:00:37","guid":{"rendered":"https:\/\/www.pharglass.com\/?p=2199"},"modified":"2026-05-29T04:00:39","modified_gmt":"2026-05-29T04:00:39","slug":"how-oral-liquid-bottle-manufacturers-produce-safe-and-sterile-pharmaceutical-packaging-containers","status":"publish","type":"post","link":"https:\/\/www.pharglass.com\/de\/how-oral-liquid-bottle-manufacturers-produce-safe-and-sterile-pharmaceutical-packaging-containers\/","title":{"rendered":"How Oral Liquid Bottle Manufacturers Produce Safe and Sterile Pharmaceutical Packaging Containers"},"content":{"rendered":"

Introduction<\/h2>\n\n\n\n

Oral liquid medications\u2014including syrups, suspensions, solutions, and drops\u2014represent a significant segment of the global pharmaceutical market. The containers that hold these products, commonly known as oral liquid bottles<\/strong>, must meet stringent safety and sterility requirements to protect patient health. Unlike injectable vials that require terminal sterility, oral liquid bottles are typically not terminally sterilized after filling; instead, they must be manufactured with extremely low bioburden and be free from pathogenic microorganisms. However, the manufacturing process itself involves multiple critical steps to ensure that the container does not introduce contaminants into the drug product.<\/p>\n\n\n\n

The global pharmaceutical glass packaging market was valued at approximately USD 21.5 billion in 2025 and is projected to grow at a CAGR of 6.8% through 2032, driven by increasing demand for oral liquid formulations, especially in pediatric and geriatric care. As a professional supplier of high-quality pharmaceutical packaging materials, PharGlass<\/strong> specializes in the production of oral liquid bottles made from borosilicate glass tubes, along with rubber stoppers, aluminum plastic caps, and other primary packaging components. With OEM\/ODM support, strict quality control systems, and reliable global delivery, PharGlass ensures that every bottle leaving our facility meets the highest standards of safety and cleanliness.<\/p>\n\n\n\n

Raw Material Selection and Pretreatment: The Foundation of Chemical Stability<\/h2>\n\n\n\n

The production of safe oral liquid bottles begins long before the glass is melted. The primary raw material is pharmaceutical\u2011grade glass tubing, typically complying with low\u2011borosilicate or medium\u2011borosilicate standards according to national and international pharmacopoeias (e.g., USP <660>, EP 3.2.1). The chemical composition of the glass directly determines its hydrolytic resistance and overall chemical stability. Inadequate chemical stability can lead to the leaching of alkali ions (e.g., sodium, potassium) and other undesirable substances into the oral liquid drug product during long\u2011term storage, potentially altering pH, causing precipitation, or even generating toxic leachables.<\/p>\n\n\n\n

Unter PharGlass<\/strong>, each batch of incoming glass tubing undergoes rigorous incoming inspection, including:<\/p>\n\n\n\n

    \n
  • Coefficient of thermal expansion (CTE)<\/strong>: Ensuring dimensional compatibility with downstream processing equipment.<\/li>\n\n\n\n
  • Hydrolytische Best\u00e4ndigkeit<\/strong> (tested per USP <660> or ISO 719): Measuring the amount of alkali released from the glass surface under controlled conditions. Low\u2011borosilicate glass typically achieves Class HGA1 (highest resistance).<\/li>\n\n\n\n
  • Acid resistance<\/strong> (ISO 1776) and surface defect inspection<\/strong>: Detecting any pre\u2011existing cracks or inclusions that could become failure points.<\/li>\n<\/ul>\n\n\n\n

    Only glass tubing that meets these specifications is released for production. This strict material control ensures that the finished oral liquid bottle will not compromise the drug product\u2019s stability or safety over its intended shelf life.<\/p>\n\n\n\n

    Forming and Primary Cleaning: Molding the Bottle Under Controlled Conditions<\/h2>\n\n\n\n

    Once raw glass tubing is approved, it enters the forming stage. The glass tube is fed into a high\u2011temperature forming machine (typically a rotary or linear vial\/bottle forming line), where it is heated in a furnace to approximately 800\u20131,200\u00b0C until soft. Using either blow\u2011forming or drawing processes, the softened tube is shaped into the final bottle geometry\u2014including the neck finish, body contours, and any design features such as graduation marks or grip ridges.<\/p>\n\n\n\n

    During this stage, two factors are critical for maintaining cleanliness:<\/p>\n\n\n\n

    Mold Cleanliness<\/h3>\n\n\n\n

    The molds (or forming tools) that contact the softened glass must be exceptionally clean. Any microscopic organic residue or particulate on the mold surface can become embedded in the external glass surface at high temperatures, creating a permanent source of contamination. At PharGlass, molds undergo regular deep cleaning using methods such as plasma cleaning, ultrasonic degreasing, or high\u2011temperature baking to remove all organic residues and metal oxides.<\/p>\n\n\n\n

    Temperature Profile Control<\/h3>\n\n\n\n

    The heating and cooling rates must be precisely controlled. Rapid or uneven cooling can induce residual stresses that weaken the bottle or cause micro\u2011cracks, which later become sites for microbial attachment or particle shedding. Controlled annealing (gradual cooling) relieves these stresses and improves overall mechanical integrity.<\/p>\n\n\n\n

    Immediately after forming, hot bottles are subjected to a primary dust removal<\/strong> step using clean compressed air (filtered to remove oil and particulates) to blow off any loose particles generated during the forming process. This initial cleaning reduces the burden on subsequent washing stages.<\/p>\n\n\n\n

    Multi\u2011Stage Cleaning: Removing Chemical and Particulate Contaminants<\/h2>\n\n\n\n

    After forming and annealing, the bottles are still not sterile. They carry residues from the forming process (e.g., mold release agents, airborne dust, and handling contaminants). A robust cleaning process is essential to achieve a low bioburden state prior to sterilization. Typical cleaning sequences for oral liquid bottles include several interrelated stages:<\/p>\n\n\n\n

    1. Alkaline Wash<\/h3>\n\n\n\n

    An alkaline cleaning solution (e.g., sodium hydroxide or a formulated detergent) is circulated through or sprayed onto the bottles. This step saponifies and emulsifies organic residues such as oils, greases, and proteinaceous material. The solution concentration, temperature (typically 50\u201380\u00b0C), and contact time are validated to ensure consistent removal.<\/p>\n\n\n\n

    2. Acid Wash<\/h3>\n\n\n\n

    Following the alkaline wash, an acidic solution (e.g., dilute hydrochloric or citric acid) is applied. This neutralizes any remaining alkaline residues and dissolves certain metal ions (e.g., iron, aluminum) that may have deposited on the glass surface from process water or equipment.<\/p>\n\n\n\n

    3. Ultrasonic Cleaning<\/h3>\n\n\n\n

    Ultrasonic cleaning is highly effective at dislodging particles embedded in microscopic pits or crevices on the glass surface. High\u2011frequency sound waves (typically 20\u201340 kHz) create cavitation bubbles that implode near the glass surface, generating intense localized energy that lifts and removes sub\u2011micron particles. This step is especially important for oral liquid bottles intended for suspensions or solutions where visible particles are unacceptable.<\/p>\n\n\n\n

    4. Rinsing with Purified Water<\/h3>\n\n\n\n

    Multiple rinses with purified water (or water for injection, WFI, for higher\u2011grade products) remove all traces of cleaning agents and dislodged particles. The quality of rinse water is continuously monitored for conductivity, total organic carbon (TOC), and microbial count.<\/p>\n\n\n\n

    The sequence, concentration, temperature, and duration of each cleaning step must be validated through worst\u2011case challenge studies, typically using artificially soiled bottles and measuring residual contaminants by methods such as total organic carbon analysis, conductivity, or visual inspection under magnification. At PharGlass, we maintain validated cleaning protocols that are re\u2011validated annually or after any significant process change.<\/p>\n\n\n\n

    Dry Heat Sterilization and Depyrogenation: Achieving Sterility and Endotoxin Reduction<\/h2>\n\n\n\n

    After cleaning, the bottles are still not sterile\u2014they may contain viable microorganisms, albeit at very low levels. The next critical step is thermal sterilization<\/strong>, typically performed using a tunnel\u2011type dry heat sterilizer (hot air tunnel). The bottles pass through three zones on a conveyor belt: pre\u2011heating, heating (sterilization\/depyrogenation), and cooling.<\/p>\n\n\n\n

    Sterilization Conditions<\/h3>\n\n\n\n

    To achieve sterility, the bottles are exposed to dry heat at temperatures typically \u2265300\u00b0C (often 320\u2013350\u00b0C) for a defined residence time, e.g., 5\u201310 minutes. Dry heat sterilization follows first\u2011order kinetics, and the process is designed to achieve a Sterilit\u00e4tssicherungsgrad (SAL)<\/strong> of 10\u207b\u2076 for the container interior. However, it is important to note that oral liquid bottles are not required to meet the same SAL as parenteral containers; nevertheless, manufacturers aim for the lowest possible bioburden, with no pathogenic microorganisms (e.g., Staphylococcus aureus<\/em>, Pseudomonas aeruginosa<\/em>, Candida albicans<\/em>) detected.<\/p>\n\n\n\n

    Depyrogenation \u2013 Removal of Endotoxins<\/h3>\n\n\n\n

    Beyond sterilization, dry heat tunnels also achieve depyrogenation<\/strong>\u2014the inactivation or removal of bacterial endotoxins (lipopolysaccharides from Gram\u2011negative bacteria). Endotoxins are heat\u2011stable and can cause febrile reactions if introduced into the bloodstream. While oral administration typically does not result in endotoxin absorption, many oral liquid bottles are manufactured to parenteral standards as a precautionary measure for products that may come into contact with compromised mucosa or for global regulatory alignment.<\/p>\n\n\n\n

    The depyrogenation process requires higher temperatures (\u2265250\u00b0C) and longer exposure to achieve a 3\u2011log reduction in endotoxin activity, as verified by the Limulus Amebocyte Lysate (LAL) test. Most dry heat tunnels are validated to ensure that the coolest bottle in the load (the \u201ccold spot\u201d) receives the required lethality (Fh value, e.g., Fh \u2265 45 minutes at 250\u00b0C reference).<\/p>\n\n\n\n

    At PharGlass, we map temperature profiles across the sterilizer regularly and place biological indicators (e.g., Geobacillus stearothermophilus<\/em> spores for sterilization) and endotoxin indicators (e.g., E. coli<\/em> LPS) during validation runs to confirm performance.<\/p>\n\n\n\n

    Container Closure Integrity: The Final Physical Barrier<\/h2>\n\n\n\n

    Sterilized oral liquid bottles are immediately capped to prevent recontamination. The closure system\u2014typically an aluminum\u2011plastic combination cap (flip\u2011off cap) or a rubber stopper with an aluminum overseal\u2014must form a hermetic seal with the bottle\u2019s neck finish. The sealing mechanism is critical because even if the bottle interior is sterile, a compromised seal allows ingress of airborne microorganisms and moisture during storage and transport.<\/p>\n\n\n\n

    Manufacturers employ several validated Container Closure Integrity Tests (CCIT)<\/strong> to verify seal quality on each batch:<\/p>\n\n\n\n

      \n
    • Negative pressure (vacuum) leak test<\/strong>: Bottles are submerged in a dye solution (e.g., 0.1% methylene blue) under vacuum. If a leak exists, air escapes during vacuum and dye is drawn into the bottle upon pressure restoration. Visible dye inside indicates failure.<\/li>\n\n\n\n
    • Dye ingress test (color water penetration)<\/strong>: A simpler version where bottles are immersed in colored water under pressure or vacuum cycles.<\/li>\n\n\n\n
    • Headspace gas analysis<\/strong> (for larger batches): Using laser\u2011based or mass spectrometry methods to detect gas leakage\u2014more sensitive but less common for oral liquids.<\/li>\n\n\n\n
    • Torque testing<\/strong> (for screw caps): Ensuring consistent application force to achieve repeatable seal compression.<\/li>\n<\/ul>\n\n\n\n

      At PharGlass, every batch undergoes CCIT sampling according to an AQL (Acceptable Quality Limit) plan, and any batch showing seal failures is rejected or re\u2011inspected. Additionally, we validate the sealing machine parameters (cap placement force, crimping pressure) daily.<\/p>\n\n\n\n

      Environmental Controls and Cleanroom Standards<\/h2>\n\n\n\n

      The entire manufacturing process\u2014especially from cleaning through capping\u2014must take place within a controlled environment to minimize airborne particle and microbial contamination. PharGlass operates in cleanrooms that meet international standards such as ISO 14644-1.<\/p>\n\n\n\n

      Typical cleanroom classifications for oral liquid bottle production:<\/p>\n\n\n\n

        \n
      • Forming and initial cleaning<\/strong>: ISO 8 (Class 100,000) or better.<\/li>\n\n\n\n
      • Post\u2011wash handling and dry heat loading<\/strong>: ISO 7 (Class 10,000).<\/li>\n\n\n\n
      • Sterilized bottle handling, capping, and packaging<\/strong>: ISO 5 (Class 100) or better, often using laminar airflow hoods or isolators.<\/li>\n<\/ul>\n\n\n\n

        Key environmental control measures include:<\/p>\n\n\n\n

          \n
        • HEPA\u2011filtered air<\/strong>: Supplied through ceiling diffusers, with 99.97% efficiency for 0.3 \u00b5m particles.<\/li>\n\n\n\n
        • Positive pressure<\/strong>: The cleanroom is maintained at higher pressure than adjacent areas to prevent infiltration of unfiltered air.<\/li>\n\n\n\n
        • Personnel gowning<\/strong>: Operators wear sterile or clean\u2011room specific gowns (coveralls, gloves, masks, goggles) and follow strict entry\/exit procedures including air showers and hand sanitization.<\/li>\n\n\n\n
        • Surface and air monitoring<\/strong>: Regular settling plates, active air samplers, and contact plates for surfaces to quantify viable and non\u2011viable particle counts.<\/li>\n<\/ul>\n\n\n\n

          Environmental data is trended to detect any deviation before it leads to product contamination. At PharGlass, we perform quarterly cleanroom recertification and daily routine monitoring to maintain compliance with regulatory expectations (e.g., EU GMP Annex 1, which sets stringent limits for even non\u2011sterile pharmaceutical packaging).<\/p>\n\n\n\n

          Why Pharmaceutical Companies Still Re\u2011wash or Re\u2011sterilize \u2013 Understanding Sterility Assurance Levels<\/h2>\n\n\n\n

          A frequently asked question is: If the oral liquid bottle manufacturer has already washed and sterilized the containers, why do many pharmaceutical companies re\u2011wash or re\u2011sterilize them before filling? The answer lies in the conceptual difference between \u201clow bioburden\u201d<\/strong> und \u201csterile assurance\u201d<\/strong> .<\/p>\n\n\n\n

          Pharmaceutical packaging manufacturers like PharGlass deliver products that have extremely low initial bioburden, are free from specified pathogens, and have been dry\u2011heat treated to inactivate most microorganisms and endotoxins. However, the industry standard for terminally sterilized drug products (especially parenterals) is a Sterility Assurance Level (SAL) of 10\u207b\u2076\u2014i.e., no more than one viable microorganism per one million units. Achieving such a high probability of sterility typically requires terminal sterilization of the filled product<\/strong> (e.g., autoclaving the filled oral liquid bottle) or aseptic filling with online sterilization<\/strong> just before filling.<\/p>\n\n\n\n

          Moreover, transportation, handling, and storage after the original sterilization step can potentially recontaminate the bottle exterior or interior if packaging is damaged. Consequently, many pharmaceutical companies prefer to receive non\u2011sterile but low\u2011bioburden<\/strong> bottles and perform their own validated washing and sterilization (e.g., a tunnel washer\/dry heat sterilizer integrated with their filling line). This gives them complete control over the chain of sterility from container to sealed drug product.<\/p>\n\n\n\n

          At PharGlass, we offer both sterile\u2011ready (gamma or dry heat sterilized, double\u2011bagged) and non\u2011sterile (low bioburden, cleaned) options, allowing customers to choose based on their filling line configuration and regulatory strategy.<\/p>\n\n\n\n

          Process Validation and Quality Control<\/h2>\n\n\n\n

          Safety and sterility cannot be tested into a product\u2014they must be built into the process. Therefore, every stage described above is subject to rigorous process validation<\/strong> and ongoing in\u2011process control<\/strong>.<\/p>\n\n\n\n

          Key validation activities include:<\/p>\n\n\n\n